tw0122
6 months ago
Hold $7- 7.42 let’s see if it’s stays up.. NEW YORK, March 4, 2024 /PRNewswire/ -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (OTCPK: LEAS) a US-based biotechnology company ("ANEW") focused on developing cell and gene- based treatments to affect aging and age-related diseases, announced that is has been granted and issued a patent in China, number CN 117126829 A for the use of ANEW's Klotho protein and Klotho gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases. This intellectual property was licensed by ANEW from UNIVERSITAT AUTÒNOMA DE BARCELONA (UAB) and INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (ICREA) in Barcelona, Spain on an exclusive worldwide basis and ANEW paid for all patent costs associated with obtaining –the patent.
trader59
7 months ago
So, essentially all of the IPO stock (and the cash in the treasury) is being redeemed, leaving the coffers essentially bare. Seems the common shareholders knew better than the $60M valuation crap on an OTC company trading for a fraction of that with nothing going on. The O/S when it settles will be 3.5M-sh, 9.5M-ish when they give the stock to the ANEW folks (dilution), and you'll have a company that hasn't done jack for a couple years with no cash to do anything with, even after the business combination, with 9.5M shares in the O/S at an unknown price. Right out of the gate, they're going to have to do an offering to raise cash.
NASDAQ investors pay attention to business performance. When they see the balance sheet of this combined company with nothing going on and nothing to do it with, they're not going to be lining up to get in on an offering and are going to laugh at the $60M "valuation" RWOD assigned to it.